Introduction {#s1}
============

Neurocritically ill patients often require brain magnetic resonance imaging (MRI) in addition to conventional neurological evaluations. Brain MRI can reveal structural lesions with a high sensitivity due to its excellent spatial resolution and enhanced soft tissue contrast ([@B1]--[@B3]). To acquire MRI images, patients\' cooperation is imperative. However, keeping patients with brain dysfunction immobilized in a dark, noisy MRI scanner is challenging and may require administration of sedative agents to ensure motion-artifact-free images ([@B4]--[@B8]). The use of sedative agents may not always guarantee patients\' cooperation and it may even exert side effects. In addition, prolonged MRI duration due to uncooperative patients may increase the occurrence of adverse events due to withheld care management upon absence from the neurological intensive care unit (neuro-ICU) ([@B9]). Therefore, a proper sedation regimen is crucial to manage neurocritically ill patients undergoing MRI.

Dexmedetomidine, an α-2 adrenoreceptor agonist, has been widely used in intensive care units due to its beneficial effects in conscious sedation, anxiety relief, and pain control, associated with minimal or absent respiratory depression ([@B10]). However, the use of dexmedetomidine for sedation of neurocritically ill patients undergoing MRI has several limitations, such as a delayed onset of sedative action, and cardio-inhibitory effects such as hypotension and bradycardia ([@B10]). Ketamine, a phencyclidine analog and antagonist of the N-methyl-d-aspartate receptor, is characterized by a rapid-onset, short-acting sedation effect and preservation of airway reflexes ([@B11]). Opposite to dexmedetomidine, ketamine exerts cardio-stimulatory effects including hypertension and tachycardia ([@B11]). Thus, a combination of dexmedetomidine and ketamine (DEX--KET) might counterbalance the side effects and enhance the beneficial effects of each drug. However, to our knowledge, the use of DEX--KET has not been evaluated for MRI sedation.

This study investigated the efficacy and safety of DEX--KET for MRI sedation in neurocritically ill patients.

Methods {#s2}
=======

Study Population
----------------

This is quasi-experimental study to evaluate efficacy and safety of DEX--KET for MRI sedation in neurocritically ill patients compared with midazolam for MRI sedation. It was performed at the Asan Medical Center, Seoul, Korea, between August 1, 2014 and October 31, 2017. According to our management protocol, brain MRI was considered for all patients with presumed brain diseases, excluding those who did not have diagnostic equipoise or did not need follow-up scans following previous computed tomography or MRI before admission to the neuro-ICU. MRI was also not performed when patients or their proxy did not consent or when a medical condition contraindicated an MRI scan. In this study, we included consecutive patients who (1) were ≥18 years of age; (2) underwent brain MRI at admission to the neuro-ICU; and (3) received midazolam or DEX--KET for MRI sedation. We excluded patients when (1) they were receiving continuous infusion of sedative agents for critical care in the neuro-ICU; (2) they underwent follow-up MRIs; and (3) they underwent other diagnostic studies outside the neuro-ICU at the time of transportation to the MRI room.

This study was approved by the institutional review board of the Asan Medical Center, and the need for written informed consent was waived due to the retrospective nature of the study.

Sedation Protocol
-----------------

On August 1, 2016, we implemented a written protocol for MRI sedation for the first time. Until then, MRI sedation was performed by routinely preparing a bolus dose (2--3 mg) of midazolam, when patients were transported to the MRI room and administering it intravenously if the patients behaved (or were expected to behave) uncooperatively. If the sedation effects of the injection proved insufficient, additional doses of midazolam were administered up to 10 mg, provided that the patients\' vitals were stable. For this study, the patients who received this type of sedation were defined as the MIDA group. Treating physician and/or interns routinely accompanied patients while the patients were transported between the neuro-ICU and the MRI room. During performing MRI, the patient\'s vital signs including heart rate, respiratory rate, and oxygen saturation were routinely monitored. Following implementation of the new MRI sedation protocol, patients who need MRI are routinely screened for the following criteria, which indicate the need for sedation: (1) agitation \[the Richmond Agitation-Sedation Scale (RASS) ≥1\] over the preceding 24 h, (2) need for physical restraints, (3) recent failure to complete a neuroimaging study, and (4) recent need for sedatives in neuroimaging studies. When patients met the criteria for MRI sedation, they were further screened for the following criteria, exclusive of DEX--KET administration: (1) QTc prolongation \> 550 ms on electrocardiography, (2) second- or third-degree atrioventricular block on electrocardiography, (3) severe heart failure, (4) intractable hypertension or hypotension, and (5) allergy to dexmedetomidine or ketamine. Patients meeting the inclusion criteria for MRI and not the exclusion criteria for DEX--KET were concurrently administered 35 μg of dexmedetomidine diluted in 0.9% saline intravenously over 10 min and 35 mg of ketamine diluted in 0.9% saline intravenously over 1 min using two different intravenous lines. Such bolus administration of DEX--KET was immediately performed before the patients left the neuro-ICU ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}, [Supplementary Figure 1](#SM1){ref-type="supplementary-material"}). Additional doses of DEX--KET and other sedative agents could be administered in the MRI room at the discretion of the attending physician if the sedation effects were not apparent. For the present study, patients who received a combination of dexmedetomidine and ketamine following implementation of the new MRI sedation protocol were defined as the DEX--KET group. DEX--KET was administered according to the protocol\'s inclusion criteria, whereas midazolam was administered at the discretion of the attending physician. For further analysis, a third group was defined, including the patients who were not assessed for non-cooperation *a priori* but met the indications for preemptive sedation when assessed *a posteriori*. This group was named MIDA\', and the results for the MIDA\' group were compared to those of the DEX--KET group.

Clinical Assessment and Data Acquisition
----------------------------------------

Following implementation of the new protocol, the following data were prospectively collected from our registry: inclusion and exclusion criteria for MRI sedation, RASS core, systolic and diastolic blood pressure, heart rate, respiratory rate, and oxygen saturation on pulse oximeter. Parameters subject to routine hourly measure included vital signs, RASS score, and Glasgow Coma Scale score. Other data extracted from the electronic medical records included demographic information, comorbidities including hypertension, diabetes mellitus, hypercholesterolemia, heart disease, previous stroke, history of smoking or alcohol consumption, scores from the Acute Physiology and Chronic Health Enquiry II (APACHE II), diagnosis at admission to the neuro-ICU, and the length of neuro-ICU stay.

MRI sedation was considered successful when the patient completed all ordered MRI sequences. We defined the MRI scan time as the time difference between the times of departure from and return to the neuro-ICU. Detailed information concerning the orders and acquisitions of MRI sequences was retrieved from the electronic medical records and the picture archive and communication system of the hospital. Vital signs were serially evaluated for the following time points: time 0, immediately before administration of sedative agents (midazolam or DEX--KET); time 1, immediately after bolus infusion of sedative agents; time 2, time of return to the neuro-ICU following MRI. Although we routinely checked vital signs multiple times and continuously monitored oxygen saturation using pulse oximeter while patients were out of the neuro-ICU, we documented vital signs only at aforementioned three time points. Thus, data on vital signs for the current study were obtained at these three time points which were documented on electronic medical records and the protocol sheet ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}).

Complications
-------------

Sedation-related complications included oxygen desaturation, hypotension, cardiorespiratory arrest, and aspiration pneumonia. Oxygen desaturation was defined as a decrease in oxygen saturation to \<90%. Hypotension was defined as a 40 mmHg decrease in systolic and/or diastolic blood pressure or the need to use inotropic agents within an hour following MRI sedation. Cardiorespiratory arrest was defined as a patient\'s need for endotracheal intubation or chest compressions within an hour following MRI sedation. Aspiration pneumonia was defined as the presence of a new or progressive radiographic infiltrate plus at least two of the following three clinical features: body temperature \> 38.0°C, leukocytosis or leukopenia, and purulent secretions, developing within 1 week following MRI sedation.

Statistical Analyses
--------------------

The DEX--KET group was compared with the MIDA and MIDA\' groups in terms of the baseline characteristics, clinical status, and vital signs before and after MRI sedation, as well as the MRI scan time, success in obtaining ordered MRI sequences, and occurrence of complications. In addition, patients with and without sedation-related complications were compared in terms of baseline characteristics, clinical status, and sedation regimen.

Univariate analyses were performed using the Pearson chi-square test, Fisher\'s exact test, Student\'s *t*-test, Mann--Whitney *U*-test, or Jonckheere-Terpstra test, as appropriate. Multivariate logistic regression analysis was performed to identify the independent contribution of each variable for the development of sedation-related complications. Variables with a *P* \< 0.2 in the univariate analysis were included as candidate variables in the multivariate analysis and removed by backward stepwise selection. Additional analysis using forward selection confirmed the final model. A two-tailed *P* \< 0.05 was considered indicative of significant differences in all statistical analyses. All statistical analyses were performed with SPSS version 21.0 (IBM, Armonk, NY, USA).

Results {#s3}
=======

A total of 1,342 patients were admitted to our neuro-ICU between August 1, 2014 and October 31, 2017. Prior to protocol implementation, 277 patients underwent MRI examination. Of these, 36 patients met the criteria for inclusion in the MIDA. The remaining patients were excluded based on the following reasons: no need for MRI sedation (*n* = 166); need for follow-up MRI scan (*n* = 49); and need for continuous infusion of sedative agents for critical care and/or other agents than midazolam (*n* = 26). Among the 36 patients in the MIDA group, 26 were further included in the MIDA\' group ([Supplementary Figure 2](#SM1){ref-type="supplementary-material"}). Following implementation of the new protocol, 243 patients underwent MRI examination, and 36 met the criteria to integrate the DEX--KET. The remaining patients were excluded due to the following reasons: no need for MRI sedation (*n* = 105); MRI sedation without indication for the new protocol (*n* = 40); follow-up MRI (*n* = 46); need for continuous infusion of sedative agents for critical care (*n* = 14); and need for other concurrent diagnostic studies (*n* = 2) ([Figure 1](#F1){ref-type="fig"}). The patient\'s median age was 69 years \[interquartile range (IQR), 54.5--78.0 years\], and 36 (50%) were men. The median body weight was 64.0 kg (IQR, 53.5--71.7 kg), and the median time interval between admission to the neuro-ICU and MRI examination was 2.0 days (IQR, 1.0--4.0 days) ([Table 1](#T1){ref-type="table"}).

![Flowchart of the patient selection process.](fneur-10-00416-g0001){#F1}

###### 

Baseline characteristics.

                                       **MIDA group (*n* = 36)**   **DEX--KET group (*n* = 36)**   ***P-*value**
  ------------------------------------ --------------------------- ------------------------------- ---------------
  **Demographics**                                                                                 
       Age, years                      67.0 (51.5--78.5)           72.0 (56.0--77.0)               0.454
       Sex, male                       22 (61.1)                   14 (38.9)                       0.099
       Body mass index, kg/m^2^        24.4 (22.7--26.7)           24.1 (21.9--26.2)               0.551
  **Comorbidities and risk factors**                                                               
       Hypertension                    18 (50.0)                   21 (58.3)                       0.636
       Diabetes mellitus               11 (30.6)                   11 (30.6)                       1.000
       Hypercholesterolemia            6 (16.7)                    4 (11.1)                        0.733
       Atrial fibrillation             9 (25.0)                    12 (33.3)                       0.604
       Coronary artery disease         5 (13.9)                    3 (8.3)                         0.708
       Previous stroke                 6 (16.7)                    5 (13.9)                        1.000
       Cancer                          3 (8.3)                     3 (8.3)                         1.000
       Smoking                         11 (30.6)                   13 (36.1)                       0.803
       Alcohol consumption             13 (36.1)                   10 (27.8)                       0.613
  **Diagnosis on admission**                                                                       
       Stroke                          22 (61.1)                   30 (83.3)                       0.066
       CNS infection                   7 (19.4)                    4 (11.1)                        0.512
       Seizure or status epilepticus   5 (13.9)                    2 (5.6)                         0.426
       Demyelinating disease           2 (5.6)                     0 (0)                           0.473
  **Clinical status on admission**                                                                 
       Glasgow Coma Scale              12.0 (10.0--14.0)           12.0 (10.0--14.0)               0.624
       APACHE-II score                 13.0 (10.0--7.0)            15.5 (12.5--19.5)               0.102

*MIDA, midazolam; DEX--KET, combination of dexmedetomidine and ketamine; CNS, central nervous system; APACHE-II, Acute Physiology and Chronic Health Enquiry II; MRI, magnetic resonance imaging*.

*Results presented as numbers (%) or medians (interquartile range)*.

MRI Sedation
------------

All patients within the MIDA group received 2--3 mg of midazolam upon arrival to the MRI room, whereas all patients within the DEX--KET group received 35 μg of dexmedetomidine and 35 mg of ketamine in the neuro-ICU, immediately before transportation to the MRI room. In both groups, additional sedative agents were administered in the MRI room according to the judgment of the treating physician. Eleven patients in the MIDA group received additional dosages of midazolam up to a maximum of 10 mg. Within the DEX--KET group, 10 patients needed additional medication, 7 of which received an additional combination of 35 μg of dexmedetomidine and 35 mg of ketamine, 2 received midazolam, and 1 received lorazepam. Data on medication doses in MIDA and DEX-KET groups are shown in [Supplementary Table 2](#SM1){ref-type="supplementary-material"}, and data on medication doses in MIDA\' and DEX-KET groups are shown in [Supplementary Table 3](#SM1){ref-type="supplementary-material"}. Reasons for requiring MRI sedation are shown in [Supplementary Tables 4, 5](#SM1){ref-type="supplementary-material"}. RASS changes following sedative administration are shown in [Supplementary Figure 3](#SM1){ref-type="supplementary-material"}.

Hemodynamic Changes
-------------------

At time 0, no significant differences were found between the MIDA and DEX--KET groups regarding the vital signs. At time 1, the systolic blood pressure was marginally higher in the DEX--KET group than that in the MIDA group, and at time 2, the respiratory rate was significantly lower in the DEX--KET than that in the MIDA group, whereas the heart rate was marginally higher in MIDA than that in the DEX--KET group. The heart rate (*P* = 0.037), respiratory rate (*P* = 0.022), and systolic blood pressure (*P* = 0.058) showed decreasing trends following administration of DEX--KET but not of midazolam ([Table 2](#T2){ref-type="table"}).

###### 

Sedation-related changes in vital signs.

                             **MIDA group (*n* = 36)**   ***P*-value[^a^](#TN1){ref-type="table-fn"}**   **DEX--KET group (*n* = 36)**   ***P-*value[^b^](#TN2){ref-type="table-fn"}**   ***P*-value[^c^](#TN3){ref-type="table-fn"}**
  -------------------------- --------------------------- ----------------------------------------------- ------------------------------- ----------------------------------------------- -----------------------------------------------
  Systolic blood pressure                                0.252                                                                           0.058                                           
       Time 0                131.0 (117--146.0)                                                          133.5 (124.5--148.0)                                                            0.195
       Time 1                131.5 (114.5--145.5)                                                        135.5 (127.5--157.5)                                                            0.064
       Time 2                122.0 (109.0--140.5)                                                        128.5 (113.5--143.0)                                                            0.427
  Diastolic blood pressure                               0.625                                                                           0.267                                           
       Time 0                72.5 (63.0--80.5)                                                           75.0 (61.5--86.0)                                                               0.562
       Time 1                76.0(65.5--82.0)                                                            76.0 (62.0--87.5)                                                               0.535
       Time 2                69.0 (62.5--78.5)                                                           70.0 (58.5--80.0)                                                               0.991
  Heart rate                                             0.426                                                                           0.037                                           
       Time 0                82.5 (71.0--95.5)                                                           85.5 (66.0--94.5)                                                               0.744
       Time 1                87.0 (71.0--97.5)                                                           79.5 (66.0--92.5)                                                               0.186
       Time 2                82.0 (67.5--92.5)                                                           71.0 (59.0--87.5)                                                               0.064
  Respiratory rate                                       0.221                                                                           0.022                                           
       Time 0                18.0 (14.5--21.5)                                                           19.0 (17.0--22.0)                                                               0.180
       Time 1                20.0 (18.0--21.0)                                                           19.0 (16.5--23.0)                                                               0.888
       Time 2                19.5 (18.0--21.5)                                                           16.5 (14.0--20.5)                                                               0.011
  Oxygen saturation                                      0.348                                                                           0.904                                           
       Time 0                98.0 (96.0--100.0)                                                          98.0 (96.0--99.5)                                                               0.863
       Time 1                97.0 (95.0--98.0)                                                           97.0 (96.0--99.5)                                                               0.301
       Time 2                99.0 (97.5--99.5)                                                           98.0 (96.0--99.5)                                                               0.380

*MIDA, midazolam; DEX--KET, combination of dexmedetomidine and ketamine*.

*Time 0 = immediately before administration of sedative agents; time 1 = immediately after bolus infusion of sedative agents; time 2 = soon after returning to the neurological intensive care unit*.

*Results presented as a median (interquartile range)*.

*P for trends from time 0 to time 2 in MIDA group for each vital sign*.

*P for trends from time 0 to time 2 in DEX--KET group for each vial sign*.

*P-value for difference of each vital sign between MIDA group and DEX--KET group for each time point*.

Outcome and Complications
-------------------------

While the two groups presented a similar MRI sedation success rate (83.3% in MIDA group vs. 91.7% in DEX--KET group; *P* = 0.476), the median MRI scan time was significantly shorter in DEX--KET group as compared with MIDA group \[100.0 min (IQR, 87.0--111.5 min) in MIDA group vs. 53.5 min (IQR, 45.0--60.5 min) in DEX--KET group; *P* \< 0.001\]. No differences were observed between the groups concerning the length of neuro-ICU stay.

The DEX--KET group presented a lower complication rate than the MIDA group (66.7% in MIDA group vs. 22.2% in DEX--KET group; *P* \< 0.001), including oxygen desaturation (16.7% in MIDA group vs. 2.8% in DEX--KET group), hypotension (5.6% in MIDA group vs. 0% in DEX--KET group), cardiorespiratory arrest (0% in both groups), and aspiration pneumonia (61.1% in MIDA group vs. 19.4% in DEX--KET group) ([Table 3](#T3){ref-type="table"}). History of smoking (*P* = 0.022) and initial diagnosis of stroke (*P* = 0.009) was associated with a higher risk of complications following MRI sedation. MRI sedation with DEX--KET as compared with midazolam was associated with lower risk for sedation-related complications (OR, 0.14; 95% CI, 0.05--0.41; *P* \< 0.001), and this result was confirmed by multivariate analysis (OR, 0.13; 95% CI, 0.04--0.41; *P* = 0.001) ([Table 4](#T4){ref-type="table"}). Further analyses comparing the MIDA\' and DEX--KET groups showed similar results ([Supplementary Tables 6--11](#SM1){ref-type="supplementary-material"}).

###### 

Outcomes and complications according to the MRI sedation protocol.

                                              **MIDA group (*n* = 36)**   **DEX--KET group (*n* = 36)**   ***P*-value**
  ------------------------------------------- --------------------------- ------------------------------- ---------------
  Outcomes relevant to MRI sedation                                                                       
       Success in MRI sedation                30 (83.3)                   33 (91.7)                       0.476
       MRI scan time, min                     100.0 (87.0--111.5)         53.5 (45.0--60.5)               \<0.001
       Length of neuro-ICU stay, day          4.0 (2.0--6.0)              4.0 (3.0--6.0)                  0.373
       Complications following MRI sedation   24 (66.7)                   8 (22.2)                        \<0.001
       Oxygen desaturation                    6 (16.7)                    1 (2.8)                         0.112
       Hypotension                            2 (5.6)                     0 (0)                           0.473
       Cardiorespiratory arrest               0 (0)                       0 (0)                           1.000
       Aspiration pneumonia                   22 (61.1)                   7 (19.4)                        0.001

*MRI, magnetic resonance imaging; neuro-ICU, neurological intensive care unit*.

*Results presented as numbers (%) or medians (interquartile ranges)*.

###### 

Factors associated with sedation-related complications.

                                       **Univariable analysis**   ***P*-value**   **Multivariable analysis**   ***P-*value**
  ------------------------------------ -------------------------- --------------- ---------------------------- ---------------
  **Demographics**                                                                                             
       Age, years                      1.000 (0.97--1.03)         0.852                                        
       Sex, male                       1.25 (0.49--3.18)          0.635                                        
       Body mass index, kg/m^2^        0.98 (0.86--1.12)          0.783                                        
  **Comorbidities and risk factors**                                                                           
       Hypertension                    0.93 (0.37--2.36)          0.874                                        
       Diabetes mellitus               0.62 (0.22--1.74)          0.360                                        
       Hypercholesterolemia            2.08 (0.53--8.11)          0.293                                        
       Atrial fibrillation             0.52 (0.18--1.50)          0.227                                        
       Coronary artery disease         0.72 (0.16--3.30)          0.676                                        
       Previous stroke                 0.41 (0.10--1.71)          0.223                                        
       Cancer                          2.71 (0.46--15.87)         0.268                                        
       Smoking                         0.28 (0.10--0.83)          0.022           0.34 (0.09--1.25)            0.105
       Alcohol consumption             0.56 (0.20--1.55)          0.261                                        
  **Diagnosis on admission**                                                                                   
       Stroke                          0.23 (0.07--0.69)          0.009                                        
       CNS infection                   4.11 (0.99--17.06)         0.051           4.54 (0.83--24.83)           0.081
       Seizure or status epilepticus   1.90 (0.39--9.20)          0.481                                        
       Demyelinating disease                                                                                   
  **Clinical status on admission**                                                                             
       Glasgow Coma Scale              0.83 (0.68--1.01)          0.061           0.81 (0.63--1.04)            0.960
       APACHE-II score                 1.04 (0.95--1.13)          0.400                                        
       MRI sedation, DEX--KET          0.14 (0.05--0.41)          \<0.001         0.13 (0.04--0.41)            0.001

*DEX--KET, combination of dexmedetomidine and ketamine; CNS, central nervous system; APACHE-II, Acute Physiology and Chronic Health Enquiry II; MRI, magnetic resonance imaging*.

Discussion {#s4}
==========

This study investigated the efficacy and safety of a newly implemented sedation protocol using a combination of dexmedetomidine and ketamine administered intravenously to perform brain MRI in neurocritically ill patients. A bolus dose of DEX--KET was infused over 10 min immediately before the patients were taken from the ICU into the MRI room. This preemptive sedation was conceived for uncooperative patients at a high risk of failure to complete ordered MRI sequences. Successful MRI examination was achieved in 92% of patients, although 28% of the patients required additional sedative doses. With the new sedation protocol, the median MRI scan time decreased from 100 to 54 min. Moreover, DEX--KET was related to a significantly lower rate of sedation-related complications, including oxygen desaturation, hypotension, and aspiration pneumonia, as compared with a use of midazolam. Thus, the implementation of a protocol which preemptively administer a combination of dexmedetomidine and ketamine in patients with high risks of MRI failure can be considered effective and safe.

Lack of patients\' cooperation is the most common reason for failure to complete MRI examinations ([@B12], [@B13]). It often occurs unexpectedly in the MRI room, even among patients who are usually cooperative or those who were sedated while in the ICU ([@B7]). This phenomenon is particularly prominent in patients with brain disorders. Failure to complete all ordered MRI sequences may cause the physician to miss the diagnosis, leading to failure to provide appropriate treatment. On the contrary, when a patient spends a long time in the MRI room to complete all ordered MRI sequences, the patient may be exposed to an increased risk of complications because critical care is withheld during the time spent away from the ICU. Sedative agents *per se* may also result in serious side effects. Thus, a preemptive, effective, and safe MRI sedation protocol is necessary for a successful management of critically ill patients.

Our MRI sedation protocol comprises preemptive administration of DEX--KET in the ICU prior to patients\' transportation into the MRI room. In the present study, all patients presented stable vital signs prior to transportation into the MRI room. One patient in the DEX--KET group developed oxygen desaturation in the MRI room, whereas six patients in the MIDA group experienced the same complication. Episodes of hypotension occurred in two patients of the MIDA group, but none in the DEX--KET group. Aspiration pneumonia occurred in 22 patients of the MIDA group, but only 7 in the DEX--KET group. Taken together, these results suggest that DEX--KET is safer than midazolam. However, 28% of the patients receiving DEX--KET required additional sedation, which may have been related to the low initial dose, which may be insufficient for some patients. In fact, our protocol uses a fixed dose of DEX--KET (35 μg of dexmedetomidine plus 35 mg of ketamine), whereas the usual bolus doses of dexmedetomidine and ketamine are 1 μg/kg for ICU sedation and 1--2 mg/kg for procedural sedation, respectively ([@B14]--[@B16]). The median of the patients\' body weight was 64 kg; therefore, the bolus dose of DEX--KET used in the current study was much lower than usual. The fact that a fixed dose regimen was adopted to avoid medication errors as well as to reduce the workload involved in the preparation of DEX--KET individual doses. Because the dose of each drug was low, a drug combination was used. Although the need for additional sedation could be due to DEX--KET having a shorter duration than expected, further studies are needed to investigate the optimal doses of DEX--KET for MRI sedation.

In addition to the inherent limitations of a small retrospective design, the present study has some limitations. First, midazolam was administered at the discretion of treating physicians, but DEX--KET was administered according to predefined indications. Thus, the better outcomes of the DEX--KET group as opposed to the MIDA group could result from not only the choice of drugs but also the different sedation instructions followed for each group. However, the subgroup analysis comparing the MIDA\' (patients who were not assessed for non-cooperation *a priori* but met the indications for preemptive sedation when assessed *a posteriori*) and DEX--KET groups provided similar results. Second, midazolam was administered in the MRI room, but DEX--KET was administered in the ICU. The saving of time for infusion of sedative agents before transportation to the MRI room, however, would not affect main results of the current study, because further analysis still showed a statistical significance for shorter MRI scan time after addition of 10 min (infusion time) in the DEX-KET group \[100.0 min (IQR, 87.0--111.5 min) vs. 63.5 min (IQR, 55.0--70.5 min); *P* \< 0.001\]. Actually, adoption of the new MRI sedation protocol was a bundle approach to screen uncooperative patients at risk to develop complications as well as to apply a presumably better drug regimen. Previous studies have demonstrated that protocolized critical care improves patient outcome ([@B17]). We suggest that routine screening for patients requiring MRI sedation is necessary because a substantial number of patients behave uncooperatively, leading to delays, failure, or complications during MRI examination. Further studies are needed to investigate uncooperative patients during MRI examination. Third, occurrence of delirium after MRI sedation---a major side effect of sedative agents---was not assessed. However, previous studies have shown that patients exposed to dexmedetomidine experience less delirium than those exposed to midazolam ([@B18]).

In conclusion, a protocolized sedation with DEX--KET was comparable to a non-protocolized sedation with midazolam for completion of ordered MRI sequences. However, the DEX--KET protocol was related to a shorter scan time and less complications than midazolam. A protocolized administration of DEX--KET for MRI sedation of potentially uncooperative patients is potentially effective and safe.
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